Abstract
Heart failure is a leading cause of mortality in North America and most other parts of the world. Its development is secondary to diseases such as hypertension, coronary artery disease, valvular heart disease or cardiomyopathies. Current therapies for preventing heart failure include the use of diuretics, inhibitors of the renin-angiotensin-aldosterone system and β-adrenergic receptor blockers. These treatments have been moderately successful; however, the incidence of heart failure is on the rise. In view of the limited success with existing therapies it has become very important to pursue alternative strategies. One such approach could be the use of food-derived compounds that have medical benefits, and can be administered as dietary supplements. In this context, resveratrol, a polyphenol, found predominantly in grapes and berries, and a major component of red wine, has been recently drawing significant attention for its cardioprotective properties. Current research on resveratrol has focused on examining its potential in preventing or regressing defects in cardiac structure and function in experimental models of heart disease. In this paper, we will discuss the potential of resveratrol as a nutraceutical in preventing the development of heart failure in the future.
Keywords: Resveratrol, heart failure, nutraceuticals
Current Chemical Biology
Title: Potential of Resveratrol in Preventing the Development of Heart Failure
Volume: 4 Issue: 1
Author(s): Peter Wojciechowski, Xavier Lieben Louis, Sijo Joseph Thandapilly, Liping Yu and Thomas Netticadan
Affiliation:
Keywords: Resveratrol, heart failure, nutraceuticals
Abstract: Heart failure is a leading cause of mortality in North America and most other parts of the world. Its development is secondary to diseases such as hypertension, coronary artery disease, valvular heart disease or cardiomyopathies. Current therapies for preventing heart failure include the use of diuretics, inhibitors of the renin-angiotensin-aldosterone system and β-adrenergic receptor blockers. These treatments have been moderately successful; however, the incidence of heart failure is on the rise. In view of the limited success with existing therapies it has become very important to pursue alternative strategies. One such approach could be the use of food-derived compounds that have medical benefits, and can be administered as dietary supplements. In this context, resveratrol, a polyphenol, found predominantly in grapes and berries, and a major component of red wine, has been recently drawing significant attention for its cardioprotective properties. Current research on resveratrol has focused on examining its potential in preventing or regressing defects in cardiac structure and function in experimental models of heart disease. In this paper, we will discuss the potential of resveratrol as a nutraceutical in preventing the development of heart failure in the future.
Export Options
About this article
Cite this article as:
Wojciechowski Peter, Louis Lieben Xavier, Thandapilly Joseph Sijo, Yu Liping and Netticadan Thomas, Potential of Resveratrol in Preventing the Development of Heart Failure, Current Chemical Biology 2010; 4 (1) . https://dx.doi.org/10.2174/2212796811004010084
DOI https://dx.doi.org/10.2174/2212796811004010084 |
Print ISSN 2212-7968 |
Publisher Name Bentham Science Publisher |
Online ISSN 1872-3136 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Hypertension and Angiogenesis
Current Pharmaceutical Design A Fast and Simple Conductometric Method for Verapamil Hydrochloride Determination in Pharmaceutical Formulations
Current Pharmaceutical Analysis Development of Doxorubicin Quantification by Reductive Amination
Current Analytical Chemistry Determinants of Left Ventricular Hypertrophy
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Beyond the Cardiac Myofilament: Hypertrophic Cardiomyopathy- Associated Mutations in Genes that Encode Calcium-Handling Proteins
Current Molecular Medicine Modulation of Cardiac Metabolism During Myocardial Ischemia
Current Pharmaceutical Design Targeted Cancer Therapy: The Next Generation of Cancer Treatment
Current Drug Discovery Technologies TRP Channels as A Newly Emerging Non-Voltage-Gated Ca2+ Entry Channel Superfamily
Current Pharmaceutical Design Recent Patents on Oxidative Stress-Related Biomarkers in Chronic Heart Failure: The Central Role of Endothelium and Myeloperoxidase
Recent Patents on Biomarkers MicroRNAs and Peroxisome Proliferator-Activated Receptors Governing the Differentiation of Mesenchymal Stem Cells
Current Stem Cell Research & Therapy Review on Patents for Ubiquitin-Proteasome Inhibitor as Medical Advance in Major Human Diseases
Recent Patents on Biomedical Engineering (Discontinued) Modulation of Rack-1/PKCβII Signalling By Soluble AβPPα in SH-SY5Y Cells
Current Alzheimer Research Artificial Intelligence for Epigenetics: Towards Personalized Medicine
Current Medicinal Chemistry Nitrogen Biobank for Cardiovascular Research
Current Cardiology Reviews Evaluation and Management of Atrial Fibrillation
Cardiovascular & Hematological Disorders-Drug Targets Role of Heme Oxygenase-1 in Cardiovascular Function
Current Pharmaceutical Design The Role of Asymmetric Dimethylarginine (ADMA) in Endothelial Dysfunction and Cardiovascular Disease
Current Cardiology Reviews Meet the Editorial Board
Current Drug Targets Leptin- and Leptin Receptor-Deficient Rodent Models: Relevance for Human Type 2 Diabetes
Current Diabetes Reviews Atypical Takotsubo Cardiomyopathy with Hypokinetic Left Mid-ventricle and Apical Wall Sparing: A Case Report and Literature Review
Current Cardiology Reviews